Factor IXa inhibitors as novel anticoagulants.

Article Details

Citation
Copy to clipboard

Howard EL, Becker KC, Rusconi CP, Becker RC

Factor IXa inhibitors as novel anticoagulants.

Arterioscler Thromb Vasc Biol. 2007 Apr;27(4):722-7. Epub 2007 Feb 1.

PubMed ID
17272750 [ View in PubMed
]
Abstract

Currently available anticoagulants are limited by modest therapeutic benefits, narrow clinical applications, increased bleeding risk, and drug-induced thrombophilia. Because factor IX plays a pivotal role in tissue factor (TF)-mediated thrombin generation, it may represent a promising target for drug development. Several methods of attenuating factor IX activity, including monoclonal antibodies, synthetic active site-blocked competitive inhibitors, oral inhibitors, and RNA aptamers, have undergone investigation. This review summarizes present knowledge of factor IX inhibitors with emphasis on biology, pharmacology, preclinical data, and early-phase clinical experience in humans.

DrugBank Data that Cites this Article

Drugs